Login to Your Account



Endocyte Falls on Inconclusive Phase IIb, Uncertain Phase III

By Jennifer Boggs
Managing Editor

Wednesday, December 14, 2011
Shares of Endocyte Inc. plummeted 65.3 percent Tuesday on news that the company's ovarian cancer drug EC145 appeared to be bested in a Phase IIb study and a planned Phase III study could be delayed due to doxorubicin shortages.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription